The 2018 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship has been awarded to Dr Kate Mahon, Medical Oncologist at Chris O’Brien Lifehouse, providing $60,000 to support her research into prostate cancer.

This is the fifth annual Clinical Research Fellowship to be awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) to support genitourinary cancer research.

The Fellowship was previously awarded by Tolmar Australia, which was acquired by Mundipharma in February, along with exclusive Australian and New Zealand distribution rights for prostate cancer medications Eligard® Injection and Bi Eligard® cp combination therapy.

Dr Mahon was announced as the recipient of the Fellowship surrounded by experts in the research and treatment of genitourinary cancers at the 2018 ANZUP Annual Scientific Meeting in Sydney.

“I am so pleased that Mundipharma was able to continue this significant support for research that will deliver real improvements in the treatment and management of prostate cancer,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand.

“Mundipharma is thrilled to be partnering with ANZUP to offer this Fellowship, which attracted a number of high quality applications from ANZUP’s multidisciplinary membership across Australia and from a range of institutions and professional groups.”

“Dr Mahon is an accomplished researcher and I’m excited to see what can be achieved with this support.”

Professor Ian Davis, Chair of ANZUP said Dr Mahon was a most deserving Fellowship recipient.

“Dr Mahon’s project was a very strong one in an excellent field of applications. This is a novel approach to try to understand the behaviour of prostate cancer, which we hope might give better guidance for the treatment of these men in the future,” Professor Davis said.

The Fellowship is intended for early and mid-career clinician-researchers of any health care discipline in genitourinary cancer research and provides funding for one year to the institution of the successful applicant.

“Dr Mahon’s research is focussed on the search for biomarkers that will tell clinicians which drugs will be most effective for each patient ahead of time, and how their treatment should be sequenced,” Ms Orr said.

“Ideally this will mean that a simple blood test could guide personalised prostate cancer therapy, helping clinicians give each individual patient the best possible chance.”

Dr Mahon is a Movember Prostate Cancer Foundation of Australia Clinician Scientist Award recipient, with a post-doctoral research focus on the treatment of advanced prostate cancer.

“The Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship will provide a fantastic opportunity to further my translational research goals, particularly in moving a blood-based biomarker into the clinic to directly help patients with advanced prostate cancer,” Dr Mahon said.

Prostate cancer is the third most commonly diagnosed cancer in Australia, with one in seven men expected to be diagnosed before the age of 85. It is also the third most common cause of cancer death.

About Mundipharma
Mundipharma Pty Limited is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold.

® ELIGARD is a registered trademark.